Director/PDMR Shareholding

BioVentix PLC

29 January 2024

 

Bioventix plc

("Bioventix" or "the Company")

Director Dealing

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified today that on 29 January 2024 Peter Harrison, Chief Executive Officer of the Company, sold 62,000 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at a price of 4,200 pence per Ordinary Share (the "Sale").

The Sale was facilitated to enable a new institutional investor to join the share register. Peter Harrison has undertaken not to dispose of any further Ordinary Shares for 12 months.

Following the Sale, Peter Harrison has a beneficial interest in 297,088 Ordinary Shares, representing approximately 5.7 per cent. of the issued share capital of the Company.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

For further information please contact:

Bioventix plc Peter Harrison Bruce Hiscock	Chief Executive Officer Chief Financial Officer	Tel: [phone]
Cavendish Capital Markets Limited Geoff Nash / Simon Hicks Nigel Birks / Harriet Ward	Corporate Finance Corporate Broking	Tel: [phone]

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Peter Harrison
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Bioventix plc
b)	LEI	213800225MHX7LZQY108
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 5 pence each
	Identification code	GB00B4QVDF07
b)	Nature of the transaction	Sale of Ordinary Shares
c)	Price(s) and volume(s)	62,000 Ordinary Shares 4,200 pence
d)	Aggregated information: ·     Aggregated volume ·     Price	Sale of 62,000 Ordinary Shares at 4,200 pence each
e)	Date of the transaction	29 January 2024
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

 

END